Astrazeneca Pharma India Ltd vs Medico Intercontinental Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8233 as of 05 May 15:30 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Medico Intercontinental Ltd changed from 3.2 on March 2021 to 7 on March 2025 . This represents a CAGR of 16.95% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Medico Intercontinental Ltd changed from ₹ 8.33 crore on March 2021 to ₹ 35.47 crore on March 2025 . This represents a CAGR of 33.61% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Medico Intercontinental Ltd for the Dec '25 is ₹ 20.19 crore as compare to the Sep '25 revenue of ₹ 20.95 crore. This represent the decline of -3.63% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Medico Intercontinental Ltd for the Dec '25 is ₹ 1.93 crore as compare to the Sep '25 ebitda of ₹ -0.33 crore. This represent the decline of -684% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Medico Intercontinental Ltd changed from ₹ 1.08 crore to ₹ -1.68 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Medico Intercontinental Ltd changed from 5.88 % on March 2023 to 0 % on March 2025 . This represents a CAGR of -100.00% over 3 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Medico Intercontinental Ltd

Medico Intercontinental Limited, formerly known as Intercontinental Leasing & Finance Company Limited was incorporated on August 14, 1984 in Ahmedabad, India.
The Company changed its name to 'Medico Intercontinental Limited' in December, 2018.
The Company is involved in trading of pharmaceutical products. The Company is also providing a platform to all research based bio-pharmaceutical companies reaching their novel and innovative therapies to every part of the globe.
From helping people obtain their medications to using cutting-edge scientific technology to discover new treatments, Medico's entrepreneurial spirit, teamwork-oriented culture and commitment to rare diseases create a unique platform for transforming patient outcomes.
The Company's commitment to changing the course of human health through bold pursuits in science, life-enhancing therapies and a promise to always put patients first across the continents.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Medico Intercontinental Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Medico Intercontinental Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,116 Cr while Market cap of Medico Intercontinental Ltd is 23 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Medico Intercontinental Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Medico Intercontinental Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Medico Intercontinental Ltd?

As of May 5, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8046.55. On the other hand, Medico Intercontinental Ltd stock price is INR ₹23.88.

How do dividend payouts of Astrazeneca Pharma India Ltd and Medico Intercontinental Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Medico Intercontinental Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.